Skip to main content
SpringerLink
Log in

PML with rituximab during RA treatment

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Genentech Inc, Biogen Idec.Genentech, Inc. and Biogen Idec, Inc. would like to inform you of important new safety information regarding Rituxan (Rm) (rituximab). Internet Document: [2 pages], 11 Sep 2008. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

PML with rituximab during RA treatment. React. Wkly. 1220, 2 (2008). https://doi.org/10.2165/00128415-200812200-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200812200-00002

Keywords

Search

Navigation